Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BYJournal of clinical medicine

The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective Secondary Analysis

  • Tamas Gonda1
  • Salvatore Paiella2
  • Rosalie C. Sears3
  • Erkut Borazanci4
  • Patricio M. Polanco5
  • Sonia S. Kupfer6
  • Fay Kastrinos7
  • Walter G. Park8
  • Kelly Hedger9
  • Lisa Ford9
  • Thomas King9
  • Norma A. Palma9
1 more authors
  • Randall E. Brand10
10 affiliations
  1. 1Division of Gastroenterology & Hepatology, New York University, New York, NY 10016, USA
  2. 2Pancreatic Surgery Unit, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, 37134 Verona, Italy
  3. 3Department of Molecular and Medical Genetics, Brenden-Colson Center for Pancreatic Care, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
  4. 4Department of Oncology, HonorHealth Research Institute, Scottsdale, AZ 85258, USA
  5. 5Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
  6. 6Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
  7. 7Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA
  8. 8Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA 94305, USA
  9. 9Immunovia, Inc., Durham, NC 27713, USA
  10. 10Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Read full textPDFCite

Related

  1. Tumor location in the pancreatic body/tail as an independent risk factor for early recurrence after curative resection of pancreatic ductal adenocarcinoma: a single-center retrospective study
    Lei Zhu, Mengxin Luo, Hongbin Han +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  2. Surufatinib and camrelizumab plus nab-paclitaxel–gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
    Yudong Yuan, Dongdong Zhang, Yuying Li +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  3. Coordinated upregulation of Hippo, NF-κB and interferon pathway genes in pancreatic ductal adenocarcinoma: a retrospective tissue qRT-PCR profiling study with external tumour-versus-non-tumour validation, molecular subtype and survival analyses.
    Eda Balkan, Murat Kızılkaya, Sevilay Özmen +5
    BMC gastroenterologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCDOAJ
  4. Diagnostic challenge in distinguishing intestinal endometriosis-associated carcinoma from primary colorectal adenocarcinoma: a case report
    Norie Tojo, Hisashi Kataoka, Yuko Izumi +2
    Journal of Surgical Case ReportsPeer-reviewedCC BY-NC 4.0Full textObstetrics, gynaecology & paediatricsPMC
  5. Integrated single-cell and proteomic profiling of pancreatic neoplasia identifies tissue markers that outperform established diagnostic markers in distinguishing cancer from precursor lesions.
    T. T. Tran, P. U. Nguyen Hoang, D. T. Pham +4
    medRxivPreprintCC BYFull textOncologymedRxiv

Cite

BibTeXRIS
BibTeX
@article{gonda2026pancreasure,
  title = {{The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective Secondary Analysis}},
  author = {Tamas Gonda and Salvatore Paiella and Rosalie C. Sears and Erkut Borazanci and Patricio M. Polanco and Sonia S. Kupfer and Fay Kastrinos and Walter G. Park and Kelly Hedger and Lisa Ford and Thomas King and Norma A. Palma and Randall E. Brand},
  journal = {Journal of clinical medicine},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13666322},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective Secondary Analysis
AU  - Tamas Gonda
AU  - Salvatore Paiella
AU  - Rosalie C. Sears
AU  - Erkut Borazanci
AU  - Patricio M. Polanco
AU  - Sonia S. Kupfer
AU  - Fay Kastrinos
AU  - Walter G. Park
AU  - Kelly Hedger
AU  - Lisa Ford
AU  - Thomas King
AU  - Norma A. Palma
AU  - Randall E. Brand
PY  - 2026
DA  - 2026/09/22
JO  - Journal of clinical medicine
UR  - https://europepmc.org/article/PMC/PMC13666322
SN  - 2077-0383
ER  -